Duan Xiaoyang, Shi Jian
Graduate Student of Hebei Medical University, Shijiazhuang 050000, China.
Department of Medical Oncology, Hebei Province Cancer Hospital, Shijiazhuang 050000, China.
Zhongguo Fei Ai Za Zhi. 2014 Dec;17(12):860-4. doi: 10.3779/j.issn.1009-3419.2014.12.07.
In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only influence the drug sensitivity, appear even disease progression, become the main bottleneck of its curative effect. MicroRNAs (miRNAs) is a non coding RNA and protein involved in regulating gene expression in the transcription level. Recent studies found that miRNAs involved in EGFR-TKIs resistance, which affect the sensitivity of tumor cells to treatment. In this paper, we reviewed briefly advance in miRNAs and EGFR-TKIs secondary resistance research in NSCLC.
近年来，在非小细胞肺癌（NSCLC）的靶向治疗中，尤其是在表皮生长因子受体（EGFR）突变的患者中，EGFR酪氨酸激酶抑制剂（TKI）越来越多地进入临床治疗，但EGFR-TKI耐药不仅影响药物敏感性，甚至出现疾病进展，成为其疗效的主要瓶颈。微小RNA（miRNAs）是一种参与转录水平基因表达调控的非编码RNA。最近的研究发现，miRNAs参与了EGFR-TKIs耐药，影响肿瘤细胞对治疗的敏感性。本文简要综述了NSCLC中miRNAs与EGFR-TKIs继发性耐药研究的进展。
